ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast
1. ResMed's Q3 adjusted EPS was $2.37, beating expectations slightly. 2. Quarterly sales rose 8% to $1.29 billion, matching forecasts. 3. Gross margin increased 140 basis points to 59.3%, showcasing efficiency gains. 4. Tariff exemptions under the Nairobi Protocol positively impact product costs. 5. Stock price rose 11% following the earnings report.